This clinical trial focuses on patients with hematologic cancers, which are types of cancer that affect the blood, bone marrow, and lymph nodes. The study involves a treatment using tafasitamab, a medication that is administered as a solution for infusion. Tafasitamab is a humanized monoclonal antibody, which means it is a type of protein designed to target specific cells in the body. It is used to help treat certain blood cancers by targeting and binding to a protein called CD19 found on the surface of cancer cells.

The purpose of this study is to provide continued treatment and monitor the safety of tafasitamab in patients who have already been receiving this medication in previous studies. Participants in this study will continue to receive tafasitamab as part of their treatment plan. The study will observe how patients respond to the medication over time and will monitor any side effects or adverse reactions that may occur. This ongoing treatment aims to support patients who have shown a positive response or stable disease condition with tafasitamab in earlier studies.

Throughout the study, patients will have regular visits to receive their treatment and to check on their health status. The study will last for a period of time, allowing researchers to gather important information about the long-term use of tafasitamab in treating hematologic cancers. This information will help in understanding the safety and effectiveness of the medication for patients who continue to benefit from it.